Mostrar el registro sencillo del ítem

dc.contributor.authorJabalera Ruz, Ylenia María 
dc.contributor.authorSola Leyva, Alberto 
dc.contributor.authorPeigneux, Ana
dc.contributor.authorVurro, Federica
dc.contributor.authorIglesias Salto, Guillermo Ramón 
dc.contributor.authorVílchez García, Jesús
dc.contributor.authorPérez Prieto, Inmaculada 
dc.contributor.authorAguilar Troyano, Francisco J.
dc.contributor.authorLópez Cara, Luisa Carlota 
dc.contributor.authorCarrasco Jiménez, María Paz 
dc.contributor.authorJiménez López, Concepción 
dc.date.accessioned2020-04-22T11:44:05Z
dc.date.available2020-04-22T11:44:05Z
dc.date.issued2019-08-12
dc.identifier.citationJabalera, Y., Sola-Leyva, A., Peigneux, A., Vurro, F., Iglesias, G. R., Vilchez-Garcia, J., ... & Jimenez-Lopez, C. (2019). Biomimetic Magnetic Nanocarriers Drive Choline Kinase Alpha Inhibitor inside Cancer Cells for Combined Chemo-Hyperthermia Therapy. Pharmaceutics, 11(8), 408.es_ES
dc.identifier.urihttp://hdl.handle.net/10481/61480
dc.description.abstractCholine kinase a1 (ChoKa1) has become an excellent antitumor target. Among all the inhibitors synthetized, the new compound Ff35 shows an excellent capacity to inhibit ChoKa1 activity. However, soluble Ff35 is also capable of inhibiting choline uptake, making the inhibitor not selective for ChoKa1. In this study, we designed a new protocol with the aim of disentangling whether the Ff35 biological action is due to the inhibition of the enzyme and/or to the choline uptake. Moreover, we offer an alternative to avoid the inhibition of choline uptake caused by Ff35, since the coupling of Ff35 to novel biomimetic magnetic nanoparticles (BMNPs) allows it to enter the cell through endocytosis without interacting with the choline transporter. This opens the possibility of a clinical use of Ff35. Our results indicate that Ff35-BMNPs nanoassemblies increase the selectivity of Ff35 and have an antiproliferative effect. Also, we demonstrate the effectiveness of the tandem Ff35-BMNPs and hyperthermia.es_ES
dc.description.sponsorshipThis research was funded by the Ministerio de Economía y Competitividad (CGL2013-46612 and CGL2016-76723 projects), Ramón y Cajal programme (RYC-2014-16901) and the Fondo Europeo de Desarrollo Regional (FEDER). Also, this research was aided by the Andalusian regional government (CTS-236).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectMagnetic nanoparticlees_ES
dc.subjectChoKa1 inhibitores_ES
dc.subjectDrug deliveryes_ES
dc.subjectBiomimetices_ES
dc.titleBiomimetic Magnetic Nanocarriers Drive Choline Kinase Alpha Inhibitor inside Cancer Cells for Combined Chemo-Hyperthermia Therapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/pharmaceutics11080408


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España